Breast Biopsy Market - Global Forecast 2025-2032

The breast biopsy market is experiencing a transformative period as healthcare decision-makers evaluate the integration of advanced technologies and evolving clinical protocols. This report delivers actionable insights for industry leaders looking to optimize investments, streamline operations, and navigate regulatory complexities within the global breast biopsy solutions landscape.

Market Snapshot: Breast Biopsy Market Performance and Growth Outlook

The breast biopsy market grew from USD 1.09 billion in 2024 to USD 1.20 billion in 2025 and is projected to continue expanding at a CAGR of 9.55%, ultimately reaching USD 2.27 billion by 2032. This upward trajectory reflects increased demand for minimally invasive diagnostic tools, wider adoption of innovative imaging-guided platforms, and greater emphasis on patient-centric workflow improvements across healthcare settings.

Scope & Segmentation of the Breast Biopsy Market

This comprehensive report dissects the market landscape by technology, procedure type, end user, and geography. Coverage includes current innovations, adoption patterns, and strategic positioning, supporting executives in their decision-making.

• Technology
  • Core Needle Biopsy (Automated Core Needle Biopsy Devices, Semi-Automated Core Needle Biopsy Devices)
  • Fine Needle Aspiration Needles (Echo Enhanced FNA Needles, Standard FNA Needles)
  • Vacuum-Assisted Systems (Handheld Vacuum-Assisted, Table Configured Vacuum-Assisted)
• Procedure Types
  • MRI Guided (Closed Bore, Open Bore)
  • Palpation Guided (Freehand Palpation, Grid Guided)
  • Stereotactic (Prone Stereotactic, Upright Stereotactic)
  • Ultrasound Guided (2D Ultrasound Guided, 3D Ultrasound Guided)
• End Users
  • Ambulatory Surgery Centers (Diagnostic Centers, Outpatient Surgery Centers)
  • Hospitals (Private Hospitals, Public Hospitals)
  • Specialty Clinics (Oncology Clinics, Radiology Clinics)
• Regions
  • Americas: North America (United States, Canada, Mexico); Latin America (Brazil, Argentina, Chile, Colombia, Peru)
  • Europe, Middle East & Africa: Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland); Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel); Africa (South Africa, Nigeria, Egypt, Kenya)
  • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan

Leading Companies: Hologic, Inc., Becton Dickinson and Company, General Electric Company, Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, Cook Medical, Inc., Merit Medical Systems, Inc., Cardinal Health, Inc., Medtronic plc

Key Takeaways: Strategic Insights for Decision-Makers

• Advanced imaging-guided and automation-driven biopsy technologies are reshaping diagnostic precision and patient comfort, prompting broader adoption across high-acuity care environments.
• Growing preference for modular biopsy systems enables facilities to adapt rapidly to evolving clinical workflows and integrate new device capabilities without major capital outlay.
• Collaboration between manufacturers, imaging providers, and clinical end-users is accelerating the pace of innovation, resulting in platforms with improved ergonomics, flexibility, and compatibility.
• Cross-disciplinary integration—engaging radiologists, surgeons, and pathologists—streamlines procedural pathways and supports multidisciplinary cancer care strategies.
• Vigilant scenario planning and end-user training are essential for capitalizing on next-generation biopsy tools and maximizing return on investment across diverse healthcare settings.

Tariff Impact: Supply Chain Resilience and Sourcing Strategies

Revised United States tariff policies introduced in 2025 have led to significant adjustments within the supply chains for breast biopsy equipment. Healthcare providers and manufacturers are increasingly focusing on local manufacturing alliances, dual-sourcing arrangements, and agile procurement strategies to reduce exposure to variable import duties and ensure consistent device supply.

Methodology & Data Sources

Analysis is rooted in a robust multi-phase research framework combining structured interviews, clinician surveys, peer-reviewed literature, regulatory filings, and financial disclosures. Data triangulation and regional validation ensure relevancy and reliability for stakeholders aiming to build resilient breast biopsy portfolios.

Why This Report Matters: Strategic Advantages for Senior Stakeholders

• Translate complex market dynamics into clear, actionable insights to inform procurement, technology adoption, and go-to-market strategies.
• Assess the competitive landscape, emerging regulatory factors, and supply chain shifts to support sustainable business growth and operational efficiency.
• Utilize global and regional segmentation granularity to target high-opportunity markets and align business objectives with market demand.

Conclusion

This report equips leaders with the strategic intelligence needed to navigate breast biopsy market developments, foster innovation, and advance precision diagnostics. Access in-depth analysis to drive informed decision-making across clinical and commercial domains.